Insulin preperation with longest action
First, I remember that insulins are categorized by their onset, peak, and duration of action. The question is about the longest-acting, so that's probably a basal insulin. The main types are rapid-acting, short-acting, intermediate-acting, and long-acting. Long-acting insulins include glargine (U100, U300), detemir, degludec, and NPH. But wait, NPH is intermediate-acting. The longest-acting would be the ultra-long ones. Glargine U300 and degludec have the longest duration, around 24-36 hours. Detemir is about 18-24 hours. So between glargine and degludec. I think degludec has a longer duration, maybe up to 42 hours. So the correct answer is insulin degludec.
Wait, but sometimes exams might refer to glargine U100 as the standard long-acting. But the question asks for the longest, so degludec is the latest and longest. So the correct answer is D. Insulin degludec.
Now, the options are likely A to D with different insulins. Let's assume the options include glargine, detemir, NPH, and degludec. The incorrect options would be the others. NPH is intermediate, so not correct. Detemir is long but not the longest. Glargine U100 is long but less than degludec. So the correct answer is D. Insulin degludec.
For the explanation, the core concept is the classification of insulins. The correct answer's mechanism is about the ultra-long duration due to its hexameric structure and subcutaneous absorption. The wrong options are other insulins with shorter durations. Clinical pearl: remember that degludec is the longest-acting, often used once daily for basal coverage. Correct answer is D.
**Core Concept**
The question tests knowledge of insulin pharmacokinetics, specifically the duration of action. Long-acting insulins (basal insulins) provide sustained glucose control without pronounced peaks, differing from rapid-acting or short-acting analogs used for meal coverage.
**Why the Correct Answer is Right**
**Insulin degludec** has the longest duration of action (up to 42 hours) due to its unique multihexamer structure, which delays subcutaneous absorption. It binds to the interstitial matrix, creating a depot that releases insulin slowly, maintaining stable basal levels with minimal diurnal variation. This makes it ideal for once-daily administration in managing type 1 and 2 diabetes.
**Why Each Wrong Option is Incorrect**
**Option A: Insulin glargine U100** β Has a duration of ~24 hours, shorter than degludec.
**Option B: Insulin detemir** β Duration is ~18β24 hours, less than degludec.
**Option C: NPH insulin** β Intermediate-acting (~12β18 hours), not long-acting.
**